Aeterna Zentaris Inc. (Nasdaq: AEZS) concluded a successful meeting of the clinical investigators for the confirmatory Phase 3 trial of Macrilen to evaluate adult growth hormone deficiency. Shares of the biopharmaceutical climbed 44 cents to $3.11.
Aeterna Zentaris concludes successful meeting
January 19, 2016 at 14:23 PM EST
